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Evaluation of RAS mutational status through BEAMing assay 
to monitor disease progression of metastatic colorectal 
cancer: a case report
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Since the introduction of antiepidermal growth factor 
receptor (anti-EGFR) monoclonal antibodies (moAbs), 
the treatment of metastatic colorectal cancer (mCRC) 
has become crucially dependent on the mutation profile 
of the tumour over the last two decades. Recently, 
rechallenge strategy with cetuximab-based chemotherapy 
has demonstrated to be active in a subgroup of patients 
whose tumour maintained wild-type RAS and RAF status. 
In this setting, liquid biopsy may replace tissue sample 
for the identification of specific subgroups of pretreated 
patients that may benefit from the reintroduction of 
anti-EGFR moAbs. In November 2014, a 64-year-old 
man with IVB stage BRAF, KRAS and NRAS wild-type 
mCRC was admitted in our hospital. He received FOLFIRI 
cetuximab as first-line treatment with deep and long-
lasting partial response (PR), followed by cetuximab 
maintenance therapy until January 2016. At the time of 
disease progression, FOLFIRI cetuximab regimen was 
reintroduced resulting in stabilization of disease and 
he continued with capecitabine cetuximab therapy until 
disease progression in October 2016. Then, the patient 
consecutively received FOLFOX bevacizumab, TAS-
102, regorafenib and FOLFIRI followed by de Gramont 
maintenance treatment. Finally, he was retreated with 
FOLFIRI cetuximab with disease progression within 
3 months and died in May 2019. During his clinical course, 
liquid biopsy detected two mutations: one in KRAS Cd.12 
and one in NRAS Cd. 61. The longitudinal assessment 
of RAS status offers considerable advantages in order 
to avoid side effects and economic costs for ineffective 
treatment choices. Liquid biopsy could help better monitor 
the disease and provide molecularly guided treatments. 
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Introduction
Standard approaches for tumour bearing patients 
strongly rely on histology to confirm clinical suggestions 
and provide an accurate diagnosis. Histology is also 
the main technique used to define the most appropri-
ate therapy as well as for disease monitoring. In recent 
years, molecular techniques aimed at evaluating altera-
tions in DNA that might help in clinical management 
of neoplastic patients have been developed. The main 
source of DNA for molecular analyses is represented by 
tissue, obtained either from biopsies or surgical samples. 
In both cases, only a single snap-shot of the genetic fea-
tures (and alterations) of the tumour can be derived. 
Therefore, using this kind of samples might not be rep-
resentative of the whole tumour due to its intrinsic het-
erogeneity. Moreover, when dealing with biopsies, only 
limited amount of DNA can be extracted and it may 
give not conclusive results.
Standard biopsies might also be used for disease monitor-
ing during treatment but especially in metastatic patients 
characterized by poor healthy conditions, performing 
multiple biopsies should be avoided. Based on these 
premises, the concept of liquid biopsy as a surrogate of 
tissue sample was proposed [1–7]. In recent years, tech-
nical improvements allowed to study circulating tumour 
cells (CTC) and circulating tumour DNA (ctDNA) in 
patients with advanced disease [8,9]. ctDNA has been 
shown to be associated with histotype, stage and tumour 
burden among other clinical features [4,10–12].
A high proportion (86–100%) of metastatic colorectal can-
cer (mCRC) patients show detectable ctDNA in plasma 
and 1.9–27% have mutations [11].
mCRC patients are characterized by a high frequency of 
KRAS mutations that are the main determinants of the 
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guidelines of clinical practice have been modified and 
currently mCRC patients are screened for both KRAS 
and NRAS to select the most appropriate patients to be 
treated with anti-EGFR [13]. RAS status is currently 
determined in tissue samples, either primary tumour or 
metastasis obtained by biopsies or surgery. Recently, sev-
eral methods aimed at evaluating RAS mutational status 
in plasma have been developed and optimized.
Case report
In November 2014, a 64-year-old man who had under-
gone surgical resection for a pT1N0M0 G2 colorectal 
cancer (CRC) in 2005 was admitted in our hospital. In 
October 2014, he presented with multiple thyroid nod-
ules and enlarged lymph nodes in the neck. In addition, a 
computed tomography (CT) scan showed multiple lung, 
mediastinal and lateral cervical nodal, adrenal, thyroid 
and hepatic metastases. Both thyroid and lung biopsies 
revealed the presence of a metastatic dissemination of 
CRC G3, CK20+, TTF1-. BRAF, KRAS and NRAS status 
were determined on the metastatic tissue by Maldi TOF 
mass spectrometry associated to Single Base Extension 
technology with CE-IVD Myriapod COLON status kit, 
validated on MassARRAY Analyzer 4 System (Sequenom, 
San Diego, California, USA). Being RAS wild-type, the 
patient received FOLFIRI cetuximab from December 
2014 to May 2015. Initially, he obtained a partial response 
(PR) and he continued cetuximab maintenance therapy 
until lung and adrenal disease progression in January 
2016. From January 2016 to July 2016, FOLFIRI cetux-
imab regimen was reintroduced resulting in stabilization 
of disease and he continued with capecitabine cetux-
imab therapy until lung, hepatic and adrenal disease 
progression in October 2016. From November 2016 to 
May 2017, the patient consecutively received FOLFOX 
bevacizumab for 6 months TAS-102 for 8 months, and 
regorafenib for 4 months. All these treatments were dis-
continued due to PD. In May 2018, a CT scan showed 
a lung, hepatic and nodal PD with development of ver-
tebral metastases. A palliative radiotherapy for bone 
metastases was performed with clinical benefit in June 
2018. In addition, the patient received FOLFIRI for five 
courses with PR, followed by de Gramont maintenance 
treatment from July 2018 to December 2018, until a CT 
scan demonstrated disease progression. In December 
2018, given the deep and long-lasting response with pre-
vious cetuximab-containing treatments, he was retreated 
with FOLFIRI cetuximab but rapidly progressed within 
3 months and died in May 2019. Interestingly, in March 
2018, 8 mL of peripheral blood were collected and plasma 
was used for the determination of KRAS and NRAS sta-
tus with OncoBEAM RAS CRC assay (Sysmex Inostics, 
Hamburg, Germany). When plasma was analysed, two 
mutations were detected as follows: one in KRAS Cd.12 
and another one in NRAS Cd. 61 (Fig. 1).
A schematic representation of the clinical history of the 
patient is reported in Fig. 2.
Discussion
The treatment of mCRC has undergone remarkable 
changes over the last two decades, at first with the use 





KRAS and NRAS mutations detected by OncoBEAM RAS CRC assay in KRAS codon 12 (panel A) and NRAS codon 61 (panel B). CRC, 
colorectal cancer; PR, partial response.
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antibodies (moAbs) in combination with standard 
chemotherapy and recently with the introduction of 
regorafenib and trifluridine/tipiracil [13]. Several stud-
ies have shown that the rechallenge with an anti-EGFR 
moAb could offer a benefit for chemotherapy-refractory 
patients. However, this benefit was observed in only 
a limited subgroup of molecularly selected patients, 
albeit heavily pretreated [14]. In a multicenter phase 2 
trial, 28 patients with RAS and BRAF wild-type mCRC, 
who responded to irinotecan- and cetuximab-contain-
ing first-line therapy and progressed to oxaliplatin- and 
bevacizumab-containing second-line therapy, received 
cetuximab plus irinotecan as third-line treatment. 
Overall, PRs were observed in 21% of the patients. 
In the preplanned exploratory analysis, RAS status 
in ctDNA was determined at the time of rechallenge. 
Notably, the frequency of RAS mutations in liquid biop-
sies was 48% and no PR was obtained in patients with 
RAS mutated ctDNA [15]. We described the case of a 
patient whose tumour developed a change in RAS sta-
tus during chemotherapy lines, going from wild-type 
RAS to RAS-mutant tumour (KRAS codon 12 and NRAS 
codon 13 mutations). This event led to the failure of 
cetuximab-containing chemotherapy at the time of 
retreatment. Since the switch in RAS status occurs in 
about half of the patients treated for mCRC [16], the 
longitudinal assessment of RAS status offers consid-
erable advantages in order to avoid unnecessary toxic 
effects and economic costs for ineffective treatment 
choices.
Treatment of mCRC has become deeply dependent on 
the molecular profile of the tumour. The development of 
real-time molecular monitoring of tumour characteristics 
during sequential therapies is a successful strategy in the 
direction of molecularly guided precision therapy.
Our data suggest that RAS mutations should be per-
formed in both tissue and plasma to better monitor 
the disease and define the best treatment options for 
each patient. As in this case, liquid biopsy could help 
identify patients who may benefit from a rechallenge 
strategy.
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